Candel Therapeutics, Inc. (CADL)

Candel Therapeutics' stock price has fluctuated, with a share price of $5.71 as of January 9, 2026, a 26.51% decrease from January 13, 2025. Key events include Q3 2025 earnings report on November 13, 2025, with an EPS of -$0.21, missing the consensus estimate, and Q2 2025 earnings were reported on August 14, 2025, with an EPS of -$0.09. Positive Phase 3 clinical trial results for CAN-2409 in localized prostate cancer were presented at ASTRO 2025, and encouraging interim Phase 1b data for CAN-3110 in recurrent glioblastoma was reported on October 8, 2025. Candel Therapeutics entered into a $130 million term loan facility with Trinity Capital Inc. on October 14, 2025. Candel Therapeutics hosted a virtual R&D Event on December 5, 2025, and showcased its immunotherapy leadership at SITC 2025 on November 4, 2025. Candel Therapeutics was added to multiple Russell Value Indexes in the 2025 reconstitution. Several analysts have maintained or initiated "Buy" or "Overweight" ratings for CADL.

Candel Therapeutics, as a clinical-stage biopharmaceutical company, does not have commercial products subject to traditional demand seasonality. Demand is tied to the progression of drug candidates through clinical trials and regulatory approvals.

Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for cancer. Their pipeline includes CAN-2409, an adenovirus platform product in Phase III trials for prostate cancer and Phase II trials for pancreatic and non-small cell lung cancer, and CAN-3110, a herpes simplex virus platform product in Phase Ib trials for recurrent high-grade glioma. The company also utilizes the enLIGHTEN Discovery Platform to create new viral immunotherapy candidates. Candel Therapeutics was founded in 2003 and was formerly known as Advantagene, Inc.

Candel Therapeutics is headquartered in Needham, Massachusetts, United States, and conducts clinical trials across North America and Europe.

Candel Therapeutics' brand reputation appears positive, driven by clinical advancements, regulatory designations, and favorable analyst coverage. The company has announced progress in clinical trials for CAN-2409 and CAN-3110, and analyst ratings are predominantly "Buy" or "Moderate Buy."

Candel Therapeutics has a mixed ownership structure including institutional, insider, and retail investors. Institutions hold a significant portion of the stock, with major holders including Fmr LLC, FBIOX - Biotechnology Portfolio, Acorn Capital Advisors, Llc, BlackRock, Inc., and Vanguard Group Inc. Insiders own a notable percentage of the company, with Estuardo Aguilar-Cordova being the largest individual shareholder. Retail investors hold a substantial 47% ownership.